登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H22ClKN6O
化学文摘社编号:
分子量:
461.00
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
5845770
产品名称
氯沙坦钾, European Pharmacopoeia (EP) Reference Standard
InChI key
OXCMYAYHXIHQOA-UHFFFAOYSA-N
InChI
1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
SMILES string
CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]
grade
pharmaceutical primary standard
API family
losartan
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... AGTR1(185)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
口服、强效、选择性的竞争血管紧张素II受体1型 (AT1)拮抗剂。
氯沙坦钾是一种口服、强效、选择性的竞争血管紧张素II受体1型 (AT1)拮抗剂。氯沙坦钾用于治疗高血压。
Application
Losartan potassium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Satoshi Terada et al.
The Journal of bone and joint surgery. American volume, 95(11), 980-988 (2013-06-20)
Muscle contusions are a common type of muscle injury and are frequently encountered in athletes and military personnel. Although these injuries are capable of healing in most instances, incomplete functional recovery often occurs because of the development of fibrosis in
Christiane Pees et al.
The American journal of cardiology, 112(9), 1477-1483 (2013-07-23)
Since 2008, when angiotensin II type I receptor blockade with losartan was introduced in the prevention of cardiovascular manifestation of Marfan syndrome (MFS), a specific treatment to address the cardiovascular lesions became available. The present study aimed to compare the
Li-Ping Wang et al.
Biochemical pharmacology, 85(10), 1486-1494 (2013-03-19)
The proliferation of cardiac fibroblasts is implicated in the pathogenesis of myocardial remodeling and fibrosis. Intermediate-conductance calcium-activated K⁺ channels (K(Ca)3.1 channels) have important roles in cell proliferation. However, it is unknown whether angiotensin II (Ang II), a potent profibrotic molecule
K L Goa et al.
Drugs, 51(5), 820-845 (1996-05-01)
Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor antagonist. It is the first of a new class of drugs to be introduced for clinical use in hypertension. This novel agent binds competitively and selectively to the AII
M Burnier et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 13(1), S23-S28 (1995-07-01)
The evaluation of a new drug in normotensive volunteers provides important pharmacodynamic and pharmacokinetic information as long as the compound has a specific mechanism of action which can be evaluated in healthy subjects as well as in patients. The purpose
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持